Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177 Lu-PSMA

Mohsen Beheshti; Reza Vali; Soroush Zarehparvar Moghadam; HamidReza Amini; Masoumeh Hakiminejad; GhasemAli Divband

doi:10.1097/RLU.0000000000005163

Complete Resolution of Locally Advanced Prostate Cancer After Molecular Endoradiotherapy With 177 Lu-PSMA

Clin Nucl Med. 2024 Jun 1;49(6):e276-e277. doi: 10.1097/RLU.0000000000005163. Epub 2024 Mar 25.

Authors

Mohsen Beheshti¹, Reza Vali², Soroush Zarehparvar Moghadam³, HamidReza Amini⁴, Masoumeh Hakiminejad⁵, GhasemAli Divband

Affiliations

¹ From the Division of Molecular Imaging and Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria.
² Division of Nuclear Medicine, Department of Diagnostic Imaging, The Hospital for Sick Children, Toronto, Ontario, Canada.
³ Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad.
⁴ Khatam PET/CT Center, Khatam-al-Anbia Hospital.
⁵ Nuclear Medicine Center, Jam Hospital, Tehran, Iran.

PMID: 38537212
DOI: 10.1097/RLU.0000000000005163

Abstract

A 76-year-old man with castration-resistant prostate cancer underwent 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT for restaging. A large PSMA-avid tumor with invasion to adjacent organs was noted causing gross hematuria and symptomatic anemia. Two cycles of 177 Lu-PSMA were administered, and the patient showed significant reduction of hematuria as well as declining in PSA levels. 177 Lu-PSMA therapy can be a good treatment option in patients with locally invasive tumors.

Publication types

Case Reports

MeSH terms

Aged
Humans
Lutetium* / therapeutic use
Male
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / pathology
Prostatic Neoplasms* / radiotherapy
Radioisotopes / therapeutic use

Substances

Lutetium
Lutetium-177
Pluvicto
Prostate-Specific Antigen
Radioisotopes